David Batt, MD
Rheumatology · Indianapolis, INNPI 1972547529
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $513,138 of the $577,110 with a category attached, or 88.9%. It is spread thinly across 17 manufacturers, the largest accounting for just 21.9%. Reporting peaked in 2019 at $156,390 and has fallen 54.7% since, to $70,786 in 2025. Among rheumatology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 698 payments — averaging $826.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$126K
- Amgen$100K
- Mallinckrodt Enterprises LLC$98K
- Mallinckrodt Hospital Products Inc.$94K
- Boehringer Ingelheim$57K
- AstraZeneca$39K
- plus $63K from 11 others
What the payments were for
- Consulting fees$18,2753%
- Speaking & faculty fees$513,13889%
- Travel & lodging$27,7505%
- Food & beverage$17,8333%
- Education$740%
- Gifts$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 122 | $126,498 |
| Amgen(2 entities) | 119 | $100,055 |
| Mallinckrodt Enterprises LLC | 84 | $98,058 |
| Mallinckrodt Hospital Products Inc. | 86 | $93,739 |
| Boehringer Ingelheim | 90 | $56,657 |
| AstraZeneca | 68 | $39,391 |
| Aurinia Pharma U.S., Inc. | 32 | $30,787 |
| AbbVie | 68 | $30,002 |
| UCB, Inc. | 7 | $682 |
| E.r. Squibb & Sons, L.L.C. | 8 | $283 |
| Bristol Myers Squibb | 2 | $233 |
| Johnson & Johnson | 2 | $228 |
| Cardinal Health 110 LLC | 2 | $200 |
| Pfizer | 1 | $100 |
| Lilly USA, LLC | 1 | $91 |
| Boston Scientific | 3 | $62 |
| Novartis | 3 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$577,110 in reported general payments places this provider in the 95th percentile of 106 rheumatology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 13 | $168,955 |
| Humira(Cf) PenAdalimumab | 16 | $106,008 |
| KevzaraSarilumab | 11 | $47,007 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 177 | $4,539 |
| Celecoxib | 23 | $4,441 |
| Hydroxychloroquine Sulfate | 129 | $4,223 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 100 | $4,035 |
| MethotrexateMethotrexate Sodium | 131 | $3,874 |
| Diclofenac Sodium | 85 | $3,376 |
| Leflunomide | 27 | $2,581 |
| Prednisone | 251 | $2,171 |
| Mycophenolate Mofetil | 30 | $2,036 |
| Azathioprine | 56 | $1,576 |
| Tramadol Hcl | 138 | $1,346 |
| Sulfasalazine DrSulfasalazine | 11 | $1,122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $56,657 | $168,95513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 106 rheumatology providers in Indiana.
Other rheumatology in Indianapolis
- Douglas SmithIndianapolis$147K
- Inna AroutiounovaIndianapolis$102K
- James CohenIndianapolis$76K
- James EhlichIndianapolis$27K
- Christopher WuIndianapolis$26K
- Methee SrivatanaIndianapolis$10K
- Mary JacobsIndianapolis$9K
- Randall ReedIndianapolis$7K
- Steven NeucksIndianapolis$6K
- Richard LautzenheiserIndianapolis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.